These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34185923)

  • 1. Location, location, location: Melanoma cells "living at the edge".
    Maiques O; Sanz-Moreno V
    Exp Dermatol; 2022 Jan; 31(1):82-88. PubMed ID: 34185923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment.
    Georgouli M; Herraiz C; Crosas-Molist E; Fanshawe B; Maiques O; Perdrix A; Pandya P; Rodriguez-Hernandez I; Ilieva KM; Cantelli G; Karagiannis P; Mele S; Lam H; Josephs DH; Matias-Guiu X; Marti RM; Nestle FO; Orgaz JL; Malanchi I; Fruhwirth GO; Karagiannis SN; Sanz-Moreno V
    Cell; 2019 Feb; 176(4):757-774.e23. PubMed ID: 30712866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion.
    Rodriguez-Hernandez I; Maiques O; Kohlhammer L; Cantelli G; Perdrix-Rosell A; Monger J; Fanshawe B; Bridgeman VL; Karagiannis SN; Penin RM; Marcolval J; Marti RM; Matias-Guiu X; Fruhwirth GO; Orgaz JL; Malanchi I; Sanz-Moreno V
    Nat Commun; 2020 Oct; 11(1):5315. PubMed ID: 33082334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.
    Flockhart RJ; Armstrong JL; Reynolds NJ; Lovat PE
    Br J Cancer; 2009 Oct; 101(8):1448-55. PubMed ID: 19724275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced WNT5A signaling in melanoma cells favors an amoeboid mode of invasion.
    Jobe NP; Åsberg L; Andersson T
    Mol Oncol; 2021 Jul; 15(7):1835-1848. PubMed ID: 33969605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.
    Zhang C; Smalley I; Emmons MF; Sharma R; Izumi V; Messina J; Koomen JM; Pasquale EB; Forsyth PA; Smalley KSM
    J Invest Dermatol; 2021 Apr; 141(4):840-851.e4. PubMed ID: 32890629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness.
    Meng P; Bedolla RG; Yun H; Fitzpatrick JE; Kumar AP; Ghosh R
    Mol Carcinog; 2019 Sep; 58(9):1701-1710. PubMed ID: 31124185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.
    Eriksson J; Le Joncour V; Nummela P; Jahkola T; Virolainen S; Laakkonen P; Saksela O; Hölttä E
    Oncotarget; 2016 Mar; 7(12):15065-92. PubMed ID: 26918341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BRAF for patients with melanoma.
    Arkenau HT; Kefford R; Long GV
    Br J Cancer; 2011 Feb; 104(3):392-8. PubMed ID: 21139585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination.
    Cantelli G; Orgaz JL; Rodriguez-Hernandez I; Karagiannis P; Maiques O; Matias-Guiu X; Nestle FO; Marti RM; Karagiannis SN; Sanz-Moreno V
    Curr Biol; 2015 Nov; 25(22):2899-914. PubMed ID: 26526369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
    Favre G
    Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podoplanin drives dedifferentiation and amoeboid invasion of melanoma.
    de Winde CM; George SL; Crosas-Molist E; Hari-Gupta Y; Arp AB; Benjamin AC; Millward LJ; Makris S; Carver A; Imperatore V; Martínez VG; Sanz-Moreno V; Acton SE
    iScience; 2021 Sep; 24(9):102976. PubMed ID: 34485858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET inhibitor suppresses melanoma progression
    Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
    Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
    [No Abstract]   [Full Text] [Related]  

  • 15. Surgical treatment options for stage IV melanoma.
    Wei IH; Healy MA; Wong SL
    Surg Clin North Am; 2014 Oct; 94(5):1075-89, ix. PubMed ID: 25245969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Emerging Therapeutic Landscape of Advanced Melanoma.
    Henriques V; Martins T; Link W; Ferreira BI
    Curr Pharm Des; 2018; 24(5):549-558. PubMed ID: 29366407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma: molecular pathogenesis and emerging target therapies (Review).
    Russo AE; Torrisi E; Bevelacqua Y; Perrotta R; Libra M; McCubrey JA; Spandidos DA; Stivala F; Malaponte G
    Int J Oncol; 2009 Jun; 34(6):1481-9. PubMed ID: 19424565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Podoplanin Drives Amoeboid Invasion in Canine and Human Mucosal Melanoma.
    Shinada M; Kato D; Motegi T; Tsuboi M; Ikeda N; Aoki S; Iguchi T; Li T; Kodera Y; Ota R; Hashimoto Y; Takahashi Y; Chambers J; Uchida K; Kato Y; Nishimura R; Nakagawa T
    Mol Cancer Res; 2023 Nov; 21(11):1205-1219. PubMed ID: 37493578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway.
    Rathore M; Girard C; Ohanna M; Tichet M; Ben Jouira R; Garcia E; Larbret F; Gesson M; Audebert S; Lacour JP; Montaudié H; Prod'Homme V; Tartare-Deckert S; Deckert M
    Oncogene; 2019 Jul; 38(30):5873-5889. PubMed ID: 31253871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
    Johnson AS; Crandall H; Dahlman K; Kelley MC
    J Am Coll Surg; 2015 Apr; 220(4):581-93.e1. PubMed ID: 25797743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.